Your session is about to expire
← Back to Search
Non-Invasive Brain Stimulation
Active tDCS for Multiple Sclerosis
N/A
Waitlist Available
Led By Leigh Charvet, MD
Research Sponsored by NYU Langone Health
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up final visit (month 4)
Awards & highlights
Study Summary
This trial is measuring changes in neural activity during tDCS sessions using MRI to see if there are any differences between healthy controls and those with neurological disorders.
Eligible Conditions
- Multiple Sclerosis
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ final visit (month 4)
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~final visit (month 4)
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Cerebral Metabolic Rate of Oxygen (CMRO2)
Neuronal Reactivity (NR)
Secondary outcome measures
Quality of Life in Neurological Disorders (Neuro-QOL) Score
Trial Design
3Treatment groups
Experimental Treatment
Active Control
Group I: MS PatientsExperimental Treatment2 Interventions
MS patients will be given approximately 15 minutes of active tDCS during MRI during the initial visit. After the first MRI visit, MS patients will receive remotely-supervised home tDCS treatment for a month to test the cumulative effects of tDCS. Participants will complete 20 x 2.0mA x 20 minute tDCS sessions paired with cognitive training over 4-week period (20 mins per day and weekend off) with electrodes placed to target the bilateral DLPFC. Around 3 months after the 20-session treatment, MS patients only will be asked to come to the clinic for neuropsychological assessments.
Group II: Healthy Control subgroupActive Control3 Interventions
The Healthy Control subgroup will be given approximately 15 minutes of active tDCS during MRI during the initial visit. Participants in the healthy control subgroup will be given the option to have an additional 15 minutes of brain imaging, which will include 10 minutes of simultaneous tDCS at up to 4.0mA, added to the end of their baseline scan. After the first MRI visit, HC subgroup patients will receive remotely-supervised home tDCS treatment for a month to test the cumulative effects of tDCS. Participants will complete 20 x 2.0mA x 20 minute tDCS sessions paired with cognitive training over 4-week period (20 mins per day and weekend off) with electrodes placed to target the bilateral DLPFC.
Group III: Healthy ControlsActive Control1 Intervention
Healthy Controls will be given approximately 15 minutes of active tDCS during MRI during the initial visit.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
tDCS Administration during MRI
2018
N/A
~80
Remotely-supervised Daily tDCS Administration
2018
N/A
~80
Find a Location
Who is running the clinical trial?
NYU Langone HealthLead Sponsor
1,367 Previous Clinical Trials
839,688 Total Patients Enrolled
23 Trials studying Multiple Sclerosis
2,251 Patients Enrolled for Multiple Sclerosis
Leigh Charvet, MDPrincipal InvestigatorNYU Langone Health
7 Previous Clinical Trials
326 Total Patients Enrolled
6 Trials studying Multiple Sclerosis
305 Patients Enrolled for Multiple Sclerosis
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- You have a history of seizures or epilepsy.Your test scores are much lower than normal.You have severe fear of small and enclosed spaces.You have a history of conditions that affect your thinking and understanding.You have a mental health condition that would make it difficult for you to take part in the study.You had a head injury or brain surgery in the past year, or have a medical device in your head or neck.You have a skin condition like eczema or severe rashes, open wounds, or sunburns near where the electrodes are placed.You have had important heart problems shown on an EKG test in the past.You are currently struggling with addiction to drugs or alcohol.You are currently being treated for a contagious skin condition or have been treated for one in the past year.You have a history of high blood pressure that is not well managed.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Does this research project include elderly participants?
"According to the inclusion criteria found on the clinical trial website, eligible applicants must be between the ages of 18 and 79. There are a total of 42 trials for people under 18 and 403 for people over the age of 65."
Answered by AI
Who meets the requirements for participating in this clinical trial?
"The ideal participant for this clinical trial studying multiple sclerosis should be between 18-79 years old. Right now, the study has room for 60 more individuals."
Answered by AI
Can people sign up for this experiment currently?
"The clinical trial is recruiting participants at this time, as indicated on clinicaltrials.gov. This trial was first posted on 7/9/2018, and the most recent edit was on 2/2/2022."
Answered by AI
Who else is applying?
What state do they live in?
New York
How old are they?
18 - 65
What site did they apply to?
New York University School of Medicine
What portion of applicants met pre-screening criteria?
Met criteria
Recent research and studies
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger